Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy
Lindsey R. Baden(Brigham and Women's Hospital), R H Rubin(Massachusetts General Hospital), Carolyn Schaeffer Koziol(Dana-Farber Cancer Institute), Angela Delvecchio(Massachusetts General Hospital), M. Doran(Massachusetts General Hospital), Joel T. Katz(Brigham and Women's Hospital), Jay A. Fishman(Harvard University)
Cited by 69
Related Papers
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Effect of Reducing Interns' Work Hours on Serious Medical Errors in Intensive Care Units
|New England Journal of Medicine|2004|1.8k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k